Live Breaking News & Updates on Alzheimers disease

Stay informed with the latest breaking news from Alzheimers disease on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Alzheimers disease and stay connected to the pulse of your community

Acumen Pharma Reports Positive Trial Results Of ACU193 In Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheimer's disease.

Amsterdam , Noord-holland , Netherlands , Daniel-oconnell , Acumen-pharmaceuticals-inc , More-such-health-news , Alzheimer-association-international-conference , Acumen-pharmaceuticals , Association-international-conference , Chief-executive-officer , Alzheimers-disease- , Cumen-pharma